✦ LIBER ✦

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study

✍ Scribed by C.H. Smith; K. Jackson; S.J. Bashir; A. Perez; A.L. Chew; A.M. Powell; M. Wain; J.N.W.N. Barker

Book ID: 108668875
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 344 KB
Volume: 155
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.2006.07316.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Somatization Disorder with

Treatment of Somatization Disorder with Nefazodone: A Prospective, Open-Label Study

✍ Matthew Menza; Marc Lauritano; Lesley Allen; Melissa Warman; Frank Ostella; Robe 📂 Article 📅 2001 🏛 American Academy of Clinical Psychiatrists 🌐 English ⚖ 54 KB

Mycophenolate Mofetil (CellCept®) for Ps

Mycophenolate Mofetil (CellCept®) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial

✍ Youwen Zhou; Don Rosenthal; Jan Dutz; Vincent Ho 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 131 KB

Iron sucrose with and without recombinan

Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: A prospective, randomized, open-label study

✍ Alexander Krafft; Christian Breymann 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

Treatment of severe, recalcitrant, chron

Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study

✍ E.M. Wain; M.I. Darling; R.D. Pleass; J.N.W.N. Barker; C.H. Smith 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

Levetiracetam for treatment of premenstr

Levetiracetam for treatment of premenstrual dysphoric disorder: A pilot, open-label study

✍ Zerrin Emel Kayatekin; Alex N. Sabo; Uriel Halbreich 📂 Article 📅 2008 🏛 Springer Vienna 🌐 English ⚖ 98 KB

Open-label study of infliximab treatment

Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation

✍ Antoni, Christian ;Dechant, Claudia ;Hanns-Martin Lorenz, P. D. ;Wendler, Joerg 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

## Abstract ## Objective To evaluate infliximab efficacy and safety in disease‐modifying antirheumatic drug–unresponsive psoriatic arthritis (PsA). ## Methods In a 54‐week, open‐label, compassionate‐use study, 10 patients received intravenous infliximab (5 mg/kg; weeks 0, 2, 6; individualized do